Granulomatous Infections Due to Tumor Necrosis Factor Blockade: Correction

Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections.

Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

The relationship between the use of tumor necrosis factor antagonists and onset of granulomatous infection was examined using data collected through the Adverse Event Reporting System of the US Food and Drug Administration for January 1998-September 2002. Granulomatous infections were reported at rates of approximately 239 per 100,000 patients who received infliximab and approximately 74 per 10...

Tumor necrosis factor- blockade for the treatment of acute GVHD

Despite posttransplantation immunosuppressive therapy, acute graft-versus-host disease (GVHD) remains a major cause of sickness and death. Tumor necrosis factor(TNF) is implicated in the pathophysiology of GVHD at several steps in the process. Infliximab is a genetically constructed immunoglobulin G1 (IgG1) murine–human chimeric monoclonal antibody that binds the soluble subunit and the membran...

Tumor Necrosis Factor-α Blockade and the Risk of Vasculitis

Tumor necrosis factor-alpha blockade and the risk of vasculitis